Is EyePoint, Inc. (EYPT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.7% / 30% | 28.4% / 30% | 0.0% / 30% | 34.87% / 5% | ✗ NOT HALAL |
| DJIM | 1.7% / 33% | 28.4% / 33% | 0.0% / 33% | 34.87% / 5% | ✗ NOT HALAL |
| MSCI | 5.2% / 33% | 88.6% / 33% | 0.1% / 33% | 34.87% / 5% | ✗ NOT HALAL |
| S&P | 1.7% / 33% | 28.4% / 33% | 0.0% / 33% | 34.87% / 5% | ✗ NOT HALAL |
| FTSE | 5.2% / 33% | 88.6% / 33% | 0.1% / 50% | 34.87% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -11346.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -72.2% | |
| Return on Assets (ROA) | -38.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$240M |
| Free Cash Flow | -$243M |
| Total Debt | $21M |
| Debt-to-Equity | 7.4 |
| Current Ratio | 8.9 |
| Total Assets | $364M |
Price & Trading
| Last Close | $13.06 |
| 50-Day MA | $14.74 |
| 200-Day MA | $13.25 |
| Avg Volume | 1.3M |
| Beta | 1.8 |
|
52-Week Range
$3.91
| |
About EyePoint, Inc. (EYPT)
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is EyePoint, Inc. (EYPT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), EyePoint, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is EyePoint, Inc.'s debt ratio?
EyePoint, Inc.'s debt ratio is 1.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 5.2%.
What are EyePoint, Inc.'s key financial metrics?
EyePoint, Inc. has a market capitalization of $1.0B, and revenue of $31M. Return on equity stands at -72.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.